Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities

Contributed by: Business Wire

Logo

Images

PCI Pharma Services announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities.

Business Wire embedded0

Tags

Biotechnology

Supply Chain Management

Manufacturing

Other Health

Health

General Health

Pharmaceutical

Medical Devices

Other Manufacturing

Retail

Packaging

Major Expansion

More Like This

PCI Pharma Services is investing more than $365 million in infrastructure supporting the clinical and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced drug delivery systems, with an emphasis on injectable formats. (Photo: Business Wire)

PCI Pharma Services Invests Over $365 Million in EU, US Facilities for Clinical and Commercial Supply of Advanced Drug Delivery and Drug-Device Combination Products

PCI Pharma Services enhances US manufacturing of prefilled syringes & cartridges through acquisition of Ajinomoto Althea.

Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges

PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea.

PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea

PCI becomes first drug product CDMO to navigate ICMRA multi-agency inspection process. (Photo: Business Wire)

PCI Pharma Services’ Bedford, New Hampshire Location Successfully Completes International Coalition of Medicines Regulatory Authorities Inspection

PCI Pharma Services Enters Next Phase of Growth With Strategic Investment from Bain Capital, Kohlberg, and Mubadala

PR Newswire associated0

GBI Biomanufacturing Expands Capabilities with Automated Aseptic Fill-Finish for Drug Products

PR Newswire associated0

Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

Aldena Therapeutics Selects PCI Pharma Services to Manufacture and Distribute Innovative Investigational Treatment for Dermatological Diseases